In this study, Nylon 6 (PA6) was reinforced with glass fibers and molded using different injection parameters. The PA6 samples were then subjected to fatigue tests, and the results were processed to study (i) how the glass fibers affected the PA6 fatigue displacement and (ii) which injection parameters influenced the PA6 fatigue property. To do so, single-factor experimental designs were implemented in which the control factors were the glass-fiber percentage, the melt temperature, the hold pressure, the hold time, the injection pressure, and the injection time. Correlational analyses were used to predict the relationships between the control factors and fatigue results. A two-factor design was then applied to determine the two factors that influenced the PA6 fatigue displacement the most, with analysis of variance being used to determine how the factors affected the fatigue property. In this study of injection plastic, the glass-fiber percentage of PA6 composite was found to be the main factor that affected the fatigue displacement the most.

<b><i>Objective:</i></b> Endogenous subclinical hyperthyroidism (eSCH) is defined by subnormal serum thyroid-stimulating hormone (TSH) level. There is limited evidence of metabolic changes induced by eSCH. The aim of our work was to evaluate changes in BMI and lipid parameters after radioiodine treatment in patients with grade 1 (TSH: 0.1–0.39 mlU/L) and 2 (TSH &#x3c;0.1 mlU/L) eSCH. <b><i>Design:</i></b> A retrospective study was performed on 74 patients with eSCH caused by benign autonomous nodular goiter which was treated with radioiodine. <b><i>Methods:</i></b> We assessed BMI, lipids parameters, and TSH after radioiodine therapy. The 12-month follow-up time point was used to compare the primary outcome variables. TSH was measured by the electrochemiluminescence method. <b><i>Results:</i></b> After radioiodine therapy, the absolute and relative increases in BMI at 12 months were significantly higher in the grade 2 group than in the grade 1 group (1.07 ± 0.27 kg/m² vs. 0.26 ± 0.15 kg/m², respectively; <i>p</i> = 0.023 and 4.01 ± 0.98% vs. 1.01 ± 0.56%, respectively; <i>p</i> = 0.026). Compared to baseline, significant increases in the levels of total cholesterol and LDL were observed after treatment in the grade 2 eSCH group (16.7 ± 4.5 mg/dL <i>p</i> &#x3c; 0.01 and 14.3 ± 4.1 mg/dL <i>p</i> &#x3c; 0.01, respectively) but not in the grade 1 group. In a multivariate model, a negative correlation was observed between pretreatment TSH levels and absolute BMI gain (<i>p</i> &#x3c; 0.01). <b><i>Conclusions:</i></b> After correction of eSCH, increases in BMI and LDL levels were observed only in patients with grade 2 eSCH. Pretreatment serum TSH was the main independent factor associated with BMI changes after radioiodine treatment.

No abstract